Qiagen (NYSE:QGEN) Releases Q3 2026 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its third quarter 2026 earnings guidance on Friday morning. The company provided earnings per share guidance of 0.650-0.650 for the period, compared to the consensus earnings per share estimate of 0.620. The company issued revenue guidance of $548.0 million, compared to the consensus revenue estimate of $534.1 million.

Qiagen Price Performance

Shares of Qiagen stock traded up $0.17 during trading on Friday, reaching $50.38. 4,814,352 shares of the company’s stock were exchanged, compared to its average volume of 2,742,421. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The company has a market cap of $10.38 billion, a P/E ratio of 25.82, a PEG ratio of 4.98 and a beta of 0.61. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The firm’s 50-day moving average price is $44.29 and its 200 day moving average price is $40.58.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%. The company had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. During the same quarter last year, the business posted $0.60 EPS. Qiagen’s revenue for the quarter was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, research analysts anticipate that Qiagen will post 2.43 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on QGEN shares. Morgan Stanley reissued an “overweight” rating on shares of Qiagen in a research note on Friday, September 11th. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 target price on shares of Qiagen in a report on Thursday, August 6th. Weiss Ratings upgraded Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 11th. Finally, Stifel Nicolaus set a $40.00 price target on Qiagen in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Qiagen presently has an average rating of “Hold” and a consensus target price of $44.43.

Key Qiagen News

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: EQT takeover nears completion: Qiagen agreed to be acquired by EQT in an all-cash transaction valued at approximately $12.1 billion, with an offer of €46.50 per share. A report says shareholders have unanimously accepted the offer, reducing deal uncertainty and supporting the stock’s recent strength. Qiagen: Unanimous Acceptance Takeover Nears Close
• Positive Sentiment: Strong preliminary Q3 performance: Qiagen reported preliminary revenue of $548 million and adjusted diluted EPS of $0.65, ahead of consensus expectations of $534.1 million and $0.62, respectively. The company’s updated guidance confirms the same figures, indicating stronger-than-expected operating performance. QIAGEN Reports Preliminary Q3 2026 Results
• Positive Sentiment: Options activity increased: Investors purchased 5,826 call options, approximately 94% above typical daily volume, suggesting heightened speculative interest and potentially bullish positioning around the takeover and earnings news.
• Neutral Sentiment: Analyst views were mixed: Robert W. Baird raised its price target from $50 to $52 and upgraded Qiagen to “outperform,” while JPMorgan maintained a “neutral” rating and reduced its target from $55 to $52. The revised targets imply limited additional upside outside the acquisition outcome.
• Negative Sentiment: Shareholder investigations add a risk: Brodsky & Smith and Halper Sadeh announced investigations into whether Qiagen is obtaining a fair price for shareholders. Such reviews could create headline risk or potentially delay or challenge the transaction, although no adverse finding was reported.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample preparation technologies, molecular testing solutions and bioinformatics for the life sciences and molecular diagnostics markets. The company develops products that help researchers and clinical laboratories isolate, analyze and interpret DNA, RNA and other biological materials.

Its portfolio includes sample collection and purification kits, automated laboratory instruments, PCR and next-generation sequencing assays, digital PCR solutions, bioinformatics software and related consumables.